




polymedco

# Improving colorectal cancer screening saves lives



## OC-Auto<sup>®</sup> FIT

Increase patient participation, identify cancer earlier, and reduce mortality with the only Tier 1, guideline-recommended Fecal Immunochemical Test (FIT) backed by proven clinical outcomes.<sup>1,2</sup>

**The #1 automated noninvasive CRC screening tool in the world<sup>3</sup>**



# Colorectal cancer screening saves lives

Colorectal cancer (CRC) has the second-highest death rate among cancers. **If detected at an early stage, 90% of all CRC deaths are preventable.**<sup>4</sup>

## Tier 1 recommendations support annual FIT screening for 45-75 year olds<sup>1,5,6</sup>

CRC screening guidelines and recommendations have been published by organizations including the US Preventive Services Task Force, American College of Gastroenterology, and the US Multi-Society Task Force on Colorectal Cancer.

**Primary screening method and frequency for average-risk patients:**  
FIT annually; colonoscopy every 10 years.



## The only Tier 1, guideline-recommended FIT backed by proven clinical outcomes<sup>1,2</sup>: OC-Auto FIT



"The OC-Light and the OC FIT-CHEK<sup>®</sup> family of FITs have the **best test performance characteristics** (i.e., highest sensitivity and specificity)."<sup>7</sup>

**-US Preventive Services Task Force**



"The fecal immunochemical test product [by Polymedco] is the FIT test with the **best clinical evidence** to support its use."<sup>8</sup>

**-Dr Douglas Rex, Past President of the American College of Gastroenterology (ACG)**

# OC-Auto<sup>®</sup> FIT

## Proven clinical impact

Only OC-AUTO has been proven to increase patient participation, identify cancer earlier, and reduce mortality.<sup>1,2</sup>



## Increase in patient compliance<sup>2</sup>

↑ **43.8%** from **38.9%** in 2000 to **82.7%** in 2015

## Reduction in annual CRC incidence<sup>2</sup>

↓ **25.5%**


## Reduction in cancer mortality<sup>2</sup>

↓ **52.4%**

**"Adherence to the screening program increased progressively over the years, reaching almost 90% of the target population."<sup>9</sup>**

## Proven cost reduction

In a large health system study, transitioning to FIT alone for all non-invasive screening results in a savings of approximately \$5.8 million per year.<sup>10</sup>



## Improved patient experience

Ease of use makes annual FIT screening a reality



📌 **99.8%**  
of patients returned the collection device correctly<sup>11</sup>

📌 **90%**  
of survey respondents reported that the automated test collection device was simple-to-very easy to use<sup>11</sup>

📌 **93%**  
of respondents that had previously performed the Guaiac test collection preferred the FIT test collection procedure (which is completely closed and without dietary restrictions)<sup>11</sup>

**"The best screening method is the one that gets done."**

**– Fight Colorectal Cancer**

# Meet your CRC screening goals

Polymedco provides solutions and support to optimize your screening program

Our partnership includes:

-  In-service trainings, in person or remote
-  Patient and provider educational materials
-  Patient instructions in over 40 languages
-  Business reviews to assess impact
-  Direct-to-home mailing to help improve patients' access to care



## Polymedco's FIT analyzers, OC-Auto Sensor io and Diana, are designed with laboratories in mind.

-  Increase productivity
-  Remove subjectivity of reading results
-  Update patient records automatically

|  | OC-Auto Sensor io   | OC-Auto Sensor Diana  |
|--|---|---|
| Detection of fecal occult blood in stool for colorectal cancer screening |  |  |
| Single samples with no dietary restrictions                              |  |  |
| 15 day inoculated stability  |  |  |
| # of tests per hour  | <b>88</b>   | <b>280</b>  |
| Closed sampling bottle   |  |  |
| Built-in sample bar code reader  |  |  |
| Latex agglutination immunoassay  |  |  |
| QC & calibration liquid ready  |  | -   |

## Contact a Polymedco representative and learn more today.

**References** 1. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238 2. Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. *Gastroenterology*. 2018;155(5):1383-1391. doi:10.1053/j.gastro.2018.07.017 3. Data on file internally at Polymedco, LLC (1) 4. Data & Progress. National Colorectal Cancer Roundtable. May 10, 2023. Accessed July 11, 2023. <https://nccr.org/data-progress/> 5. Shaikat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. *Am J Gastroenterol*. 2021;116(3):458-479. doi:10.14309/ajg.000000000000122 6. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol*. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174 7. UPSTF. Public comment on draft recommendation statement and draft evidence review: screening for colorectal cancer. Accessed July 7, 2023 <http://www.uspreventiveservicestaskforce.org/Announcements/News/Item/public-comment-on-draft-recommendation-statement-and-draftevidence-review-screening-for-colorectal-cancer> 8. NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals. Published June 13, 2013. <https://www.jwatch.org/na31297/2013/06/13/finding-best-fit-colorectalcancer-screening> 9. Roselló S, Simón S, Cervantes A. Programmed colorectal cancer screening decreases incidence and mortality. *Transl Gastroenterol Hepatol*. 2019;4:84. doi:10.21037/tgh.2019.12.13. 2018;4:84-84. 10. Allen CJ, Bloom N, Rothka M, et al. Comprehensive Cost Implications of Commercially Available Noninvasive Colorectal Cancer Screening Modalities. *J Am Coll Surg*. 2023;10. doi:10.1097/XCS.0000000000000768 11. Data on file internally with Polymedco, LLC (2)

Image content features models and is meant solely for illustrative purposes.

**Polymedco, LLC**

510 Furnace Dock Road  
Cortlandt Manor, NY 10567

polymedco.com

© Copyright 2023 | September 2023

polymedco

80934-01